NCT06459791 Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
| NCT ID | NCT06459791 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Curie |
| Condition | Metastatic Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2024-12-06 |
| Primary Completion | 2027-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2024-12-06 with a primary completion date of 2027-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.
Eligibility Criteria
Inclusion Criteria: 1. Patient over 18 years of age 2. Advanced breast cancer 3. Triple-negative phenotype (HR-/HER2-) or HR+/HER2- after hormone resistance (progression after treatment with hormone therapy + CDK4/6 inhibitor) 4. Tumor measurable according to RECISTv1.1 criteria, accessible to biopsy 5. Performans Status 0-1 Exclusion Criteria: 1. More than 3 lines of chemotherapy in the advanced setting (excluding hormone therapy/CDK4/6 inhibitor) 2. Progressive brain metastases 3. Leptomeningeal metastasis
Contact & Investigator
Luc CABEL, MD
PRINCIPAL INVESTIGATOR
Institut Curie
Frequently Asked Questions
Who can join the NCT06459791 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06459791 currently recruiting?
Yes, NCT06459791 is actively recruiting participants. Contact the research team at drci.promotion@curie.fr for enrollment information.
Where is the NCT06459791 trial being conducted?
This trial is being conducted at Paris, France, Paris, France, Saint-Cloud, France.
Who is sponsoring the NCT06459791 clinical trial?
NCT06459791 is sponsored by Institut Curie. The principal investigator is Luc CABEL, MD at Institut Curie. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.